Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
Total Valuation
Iterum Therapeutics has a market cap or net worth of $43.57M. The enterprise value is $68.71M.
Market Cap$43.57M
Enterprise Value$68.71M
Share Statistics
Iterum Therapeutics has 34,581,406 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,581,406
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Iterum Therapeutics’s return on equity (ROE) is 6.07 and return on invested capital (ROIC) is -68.59%.
Return on Equity (ROE)6.07
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-68.59%
Return on Capital Employed (ROCE)-0.69
Revenue Per Employee0.00
Profits Per Employee-2.75M
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Iterum Therapeutics is -1.41. Iterum Therapeutics’s PEG ratio is 0.02.
PE Ratio-1.41
PS Ratio0.00
PB Ratio-8.54
Price to Fair Value-8.54
Price to FCF-1.30
Price to Operating Cash Flow-1.30
PEG Ratio0.02
Income Statement
In the last 12 months, Iterum Therapeutics had revenue of 0.00 and earned -24.77M in profits. Earnings per share was -1.26.
Revenue0.00
Gross Profit-254.00K
Operating Income-18.70M
Pretax Income-24.53M
Net Income-24.77M
EBITDA-18.70M
Earnings Per Share (EPS)-1.26
Cash Flow
In the last 12 months, operating cash flow was -26.77M and capital expenditures 0.00, giving a free cash flow of -26.77M billion.
Operating Cash Flow-26.77M
Free Cash Flow-26.77M
Free Cash Flow per Share-0.77
Dividends & Yields
Iterum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.15
52-Week Price Change-29.56%
50-Day Moving Average1.29
200-Day Moving Average1.39
Relative Strength Index (RSI)40.46
Average Volume (3m)350.08K
Important Dates
Iterum Therapeutics upcoming earnings date is May 9, 2025, TBA Not Confirmed.
Last Earnings DateFeb 7, 2025
Next Earnings DateMay 9, 2025
Ex-Dividend Date―
Financial Position
Iterum Therapeutics as a current ratio of 1.41, with Debt / Equity ratio of -1115.76%
Current Ratio1.41
Quick Ratio1.41
Debt to Market Cap0.89
Net Debt to EBITDA-1.15
Interest Coverage Ratio7.41
Taxes
In the past 12 months, Iterum Therapeutics has paid -240.00K in taxes.
Income Tax-240.00K
Effective Tax Rate<0.01
Enterprise Valuation
Iterum Therapeutics EV to EBITDA ratio is -3.01, with an EV/FCF ratio of -2.10.
EV to Sales0.00
EV to EBITDA-3.01
EV to Free Cash Flow-2.10
EV to Operating Cash Flow-2.10
Balance Sheet
Iterum Therapeutics has $24.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $21.41M billion.
Cash & Marketable Securities$24.13M
Total Debt$0.00
Net Cash$21.41M
Net Cash Per Share$0.62
Tangible Book Value Per Share-$1.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Iterum Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside843.40% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast55.67%